Partnership referenced within the GPT-Rosalind announcement as a named qualified customer for the life-sciences model (no separate dedicated story page found).
Partnership referenced within the GPT-Rosalind announcement as a named qualified customer for the life-sciences model (no separate dedicated story page found).
OpenAI supplies AI to pharma through ChatGPT Enterprise and GPT-Rosalind, a frontier model purpose-built for life-sciences reasoning, literature synthesis and experimental design.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by OpenAI on its own site — read the original case study on openai.com ↗
Note: 403 Forbidden on repeated attempts - the referenced page (openai.com/index/introducing-gpt-rosalind/) blocks automated fetches, no content retrieved.
Related use cases
- 01OpenAI's dedicated healthcare vertical page/launch post.
- 02Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 03follow-up update to the life-sciences model.
- 04"How Amgen uses GPT-5": Amgen applies GPT-5/frontier models to help accelerate delivery of potential new therapies; found GPT-5 met scientific-accuracy standards.
- 05Moderna and OpenAI partner to accelerate development of treatments; ChatGPT Enterprise deployed to thousands of employees company-wide.
- 06Longevity biotech collaborated with OpenAI to build and research GPT-4b micro, a version of GPT-4o specialized for protein engineering.